In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Millennium Velcade Has 50%-60% Of Third-Line Multiple Myeloma Market

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Millennium’s Velcade captured 50% to 60% of the third-line multiple myeloma market in the second quarter, the firm reported July 22.

You may also be interested in...



Velcade sNDA seeks full approval, second-line use

 

Velcade Shows Edge In Phase III Multiple Myeloma Trial; Fails In Colorectal

Millennium plans to submit its Phase III Velcade (bortezomib) confirmatory trial in multiple myeloma in the second half of 2004.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel